Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Arcadia Biosciences, Inc. (17D.F)

3.7200
0.0000
(0.00%)
At close: February 24 at 8:06:54 AM GMT+1
Loading Chart for 17D.F
  • Previous Close 3.7200
  • Open 3.7200
  • Bid --
  • Ask --
  • Day's Range 3.7200 - 3.7200
  • 52 Week Range 1.8000 - 7.4000
  • Volume 378
  • Avg. Volume 0
  • Market Cap (intraday) 5.085M
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7800
  • Earnings Date May 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

www.arcadiabio.com

9

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 17D.F

View More

Performance Overview: 17D.F

Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

17D.F
34.74%
S&P 500 (^GSPC)
4.72%

1-Year Return

17D.F
97.87%
S&P 500 (^GSPC)
11.67%

3-Year Return

17D.F
89.98%
S&P 500 (^GSPC)
35.63%

5-Year Return

17D.F
97.71%
S&P 500 (^GSPC)
97.98%

Compare To: 17D.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 17D.F

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    4.20M

  • Enterprise Value

    612.61k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.14

  • Price/Book (mrq)

    0.93

  • Enterprise Value/Revenue

    0.14

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -139.50%

  • Return on Assets (ttm)

    -28.06%

  • Return on Equity (ttm)

    -45.62%

  • Revenue (ttm)

    5.04M

  • Net Income Avi to Common (ttm)

    -4.32M

  • Diluted EPS (ttm)

    -2.7800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.24M

  • Total Debt/Equity (mrq)

    2.49%

  • Levered Free Cash Flow (ttm)

    -1.39M

Research Analysis: 17D.F

View More

Company Insights: 17D.F

Research Reports: 17D.F

View More